SkiStar AB
SkiStar publishes Annual and Sustainability Report for 2023/24
SkiStar publishes Annual and Sustainability Report for 2023/24
SkiStar AB (publ) publishes the Annual and Sustainability Report for the financial year 2023/24 on SkiStar’s web page, https://investor.skistar.com/en. The Swedish Annual Report 2023/24 is also available on SkiStar's website in European Single Electronic Format (ESEF).
This information is information that SkiStar AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out below, at 20 November 2024, 07.00 a.m. CET.
Further information can be reached from:
Stefan Sjöstrand, CEO, tel +46 (0)280 841 60.
Martin Almgren, CFO, tel +46 (0)280 841 60.
SkiStar in brief
The mountain tourism company SkiStar AB (publ) is listed on the Mid Cap list of the Nasdaq Stockholm exchange. The Group owns and operates alpine ski resorts in Sälen, Vemdalen, Åre and Hammarbybacken (Stockholm) in Sweden, and Hemsedal and Trysil in Norway. Our operations are divided into three segments: Operation of Ski Resorts, Property Development & Exploitation and Operation of Hotels. As the leading holiday organiser for Scandinavia, SkiStar’s business concept is to create memorable mountain experiences, develop sustainable destinations and offer accommodation, activities, products and services of the highest quality with our guests as our focus. For more information, see https://investor.skistar.com/en.
Attachments
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
TCM Group A/S5.8.2025 08:13:25 CEST | Press release
TCM Group A/S: Major shareholder announcement
TCM Group A/S5.8.2025 08:13:25 CEST | Pressemeddelelse
TCM Group A/S: Storaktionærmeddelelse
Tallink Grupp5.8.2025 08:00:44 CEST | Press release
AS Tallink Grupp Statistics for July 2025
ING Group5.8.2025 08:00:00 CEST | Press release
Progress on share buyback programme
Purespring Therapeutics5.8.2025 08:00:00 CEST | Press release
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom